Bristol-Myers Squibb
BMY
58.80
+0.46
+0.79%
Bristol-Myers Squibb
US · BMY
#158 by market cap
Listed 1970
58.80
+0.46
+0.79%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Quant vs Street three independent views, side by side
StockVane factor grade
B+
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Improving
2
■ Upgrades■ Downgrades
- 2 upgrades vs 0 downgrades among tracked analyst rating changes.
- Most recent: Argus Research moved from Hold to Buy on 2026-08-04.
Analyst consensus 17 analysts
Buy
Avg price target 67.25 +14.4%
Price target rangecurrent 58.80
Low40.00
Avg67.25
High80.00
Buy 47%
Hold 47%
Sell 6%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-16 | Barclays | -- | Buy | 75.00 |
| 2026-10-30 | Morgan Stanley | -- | Sell | 40.00 |
| 2026-10-29 | William Blair | -- | Hold | -- |
| 2026-10-29 | BofA Securities | -- | Buy | 67.00 |
| 2026-10-29 | Guggenheim | -- | Buy | 75.00 |
| 2026-10-29 | Barclays | -- | Buy | 75.00 |
| 2026-10-29 | RBC Capital | -- | Hold | 64.00 |
| 2026-10-27 | Piper Sandler | -- | Buy | 78.00 |
| 2026-10-27 | RBC Capital | -- | Hold | 64.00 |
| 2026-10-26 | Piper Sandler | -- | Buy | 78.00 |
| 2026-10-19 | Goldman Sachs | -- | Hold | 63.00 |
| 2026-10-19 | RBC Capital | -- | Hold | 64.00 |
| 2026-10-16 | RBC Capital | -- | Hold | 64.00 |
| 2026-10-13 | Wells Fargo | -- | Hold | 60.00 |
| 2026-10-13 | Piper Sandler | -- | Buy | 82.00 |
| 2026-10-13 | Truist Financial | -- | Buy | 70.00 |
| 2026-10-13 | Citi | -- | Hold | 70.00 |
| 2026-10-13 | Barclays | -- | Buy | 75.00 |
| 2026-10-12 | William Blair | -- | Hold | -- |
| 2026-10-12 | Morgan Stanley | -- | Sell | 41.00 |
| 2026-10-12 | Jefferies | -- | Buy | 76.00 |
| 2026-10-12 | BMO Capital | -- | Hold | 60.00 |
| 2026-10-12 | Goldman Sachs | -- | Hold | 63.00 |
| 2026-10-12 | RBC Capital | -- | Hold | 64.00 |
| 2026-10-09 | UBS | -- | Buy | 80.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-08-04 | Argus Research | Hold → Buy | 75.00 |
| 2025-12-15 | BofA Securities | Hold → Buy | 61.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-10-29 | -- | ±3.49% | +1.35% (in line) |
| 2026/Q2 | 2026-07-30 | -- | ±3.20% | +2.79% (in line) |
| 2026/Q1 | 2026-04-30 | -- | ±4.05% | +5.21% (beat) |
| 2025/Q4 | 2026-02-05 | -- | ±3.69% | +3.30% (in line) |
| 2025/Q3 | 2025-10-30 | -- | ±4.33% | +7.09% (beat) |
| 2025/Q2 | 2025-07-31 | -- | ±4.93% | -5.81% (beat) |
| 2025/Q1 | 2025-04-24 | -- | ±5.27% | +0.33% (in line) |
| 2024/Q4 | 2025-02-06 | -- | ±5.62% | -3.84% (in line) |
| 2024/Q3 | 2024-10-31 | -- | ±4.48% | +5.91% (beat) |
| 2024/Q2 | 2024-07-26 | -- | ±6.00% | +11.44% (beat) |
| 2024/Q1 | 2024-04-25 | -- | ±3.57% | -8.51% (beat) |
| 2023/Q4 | 2024-02-02 | -- | ±5.14% | +0.08% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:02:42 · For reference only, not investment advice and not tailored to your situation.
Bristol-Myers Squibb discussion 0 comments